ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025
Definitive (chemo)radiotherapy of enteric-type adenocarcinoma of the lung: time to unmask an underrated treatment option?
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnteric-type adenocarcinoma of the lung (lung-ETAC) is an exceptionally rare variant of lung adenocarcinoma, often presenting diagnostic challenges due to its histological resemblance to colorectal adenocarcinoma. This rarity has hindered the development of standardized treatment protocols, with most management approaches being empirical. Radiotherapy is used infrequently for lung-ETAC, predominantly reserved for palliative care in metastatic cases. Recent studies, however, suggest that lung-ETAC may have a better prognosis than other lung cancer subtypes, thus raising the need to explore alternative therapeutic strategies, including radiotherapy. CASE REPORT: We present the case of a 73-year-old female with stage IIIA lung-ETAC who was treated with curative-intent radiotherapy (60 Gy in 30 fractions) in combination with platinum-based chemotherapy. Despite transient pulmonary complications, the patient exhibited an almost complete response to treatment after 2 months, achieving sustained clinical remission with no further antitumor therapies.
conclusionThis case underscores the potential role of high-dose radiotherapy as a curative treatment for locally advanced lung-ETAC. Given the limited evidence, further research is needed to better define the role of chemoradiotherapy in the management of this rare histological subtype.
Indexed as
Identifiers
40199755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.